Showing results (481-490 of 513) with videos related to

Sort By:
Pageof 52
The Journal of Rheumatology|July 7, 2023
Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working GroupYing-Ying Leung, William Tillett, Maarten de Wit, et al.
JAMA Dermatology|May 15, 2026
Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical TrialMark Lebwohl, Andrew Blauvelt, Cynthia E Kartman, et al.
JCO Clinical Cancer Informatics|September 27, 2021
Ascertainment of Veterans With Metastatic Prostate Cancer in Electronic Health Records: Demonstrating the Case for Natural Language ProcessingPatrick R Alba, Anthony Gao, Kyung Min Lee, et al.
Dermatology (Basel, Switzerland)|September 19, 2021
International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual MeetingAlison H Kohn, Afsaneh Alavi, April W Armstrong, et al.
Journal of the American Academy of Dermatology|November 19, 2025
Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitorsAndrew Blauvelt, Bruce E Strober, Guy S Eakin, et al.
Dermatology and Therapy|January 13, 2022
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 TrialDiamant Thaçi, Bruce Strober, Kenneth B Gordon, et al.
The British Journal of Dermatology|August 28, 2025
SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site InvolvementLinda Stein Gold, Alice B Gottlieb, April W Armstrong, et al.
RMD Open|February 22, 2024
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITALLaura C Coates, Robert Landewé, Iain B McInnes, et al.
JAMIA Open|July 11, 2022
An alert tool to promote lung protective ventilation for possible acute respiratory distress syndromeAndrew J Knighton, Kathryn G Kuttler, Pallavi Ranade-Kharkar, et al.
JAMA Surgery|June 4, 2025
Drug-Gene Interactions and Clinical Outcomes After Vascular Surgery in the Million Veteran ProgramSony Tuteja, William J O'Brien, Jeffrey P Ferraro, et al.
Pageof 52